INDEX
BIO-SCIENCE LAW REVIEW
VOLUME 12

CONTENTS
Subject Index i
Countries and Institutions ii
Contributors iv
Contributions iv
Case List v

Subject Index
BIOSIMILARS
Guidelines
Biosimilar guidelines – new consultation opportunity (European News) 2 78

BIOTECHNOLOGY
Patents
Eli Lilly v HGS round 2 – Warren J (Case Comment) 6 239
Eli Lilly v Human Genome Sciences (United Kingdom) 5 206
Eli Lilly v Human Genome Sciences: has the pro-patentee pendulum swung too far? (Case Comment) 3 100
UK Supreme Court finds industrial application in a biotechnology patent Human Genome Sciences Inc v Eli Lilly and Company (United Kingdom) 2 66

CONTRACTS
Entire agreement clauses
Common sense approach to entire agreement clauses
Axa Sun Life v Campbell Martin; BSkyB v HP Enterprise Services (United Kingdom) 3 112

CROSS-BORDER INJUNCTIONS
Jurisdiction
Cross-border injunctions: have they a future? Solvay v Honeywell (European News) 4 161

FOOD AND FEED
GMOs
Authorisation regime for GM food and feed in Turkey under the new GMO legislation: the simplified procedure proves simply too irresistible for applicants (Article) 1 8

GENETICALLY MODIFIED ORGANISMS
Food and feed
Authorisation regime for GM food and feed in Turkey under the new GMO legislation: the simplified procedure proves simply too irresistible for applicants (Article) 1 8

Pollens
Honey products containing GM pollen require strict marketing control in the EU Karl Heinz Bablok and others v Freistaat Bayern (European News) 2 74

HEALTHCARE
Legislation
UK Health and Social Care Act promises to improve competition in healthcare (United Kingdom) 3 113

INTELLECTUAL PROPERTY
Genetic resources
Meeting of WIPO’s Intergovernmental Committee on Intellectual Property and Genetic Resources (News) 3 115

LIFE SCIENCES
Transfer of rights
Deferred consideration and diligence obligations in life sciences agreements: the lessons from Porton Capital Technology Funds (and others) v 3M (Article) 3 83

MEDICINAL PRODUCTS
Cost
European Court affirms that public safety comes first: financial considerations cannot justify the placing on the market of unlicensed medicines (Case Comment) 4 154

Gene therapy
First gene therapy product recommended for approval in the EU (EMEA) 5 201

Information
New framework for provision of information to the general public about prescription-only medicines (European News) 2 71

Paediatric Regulation
Dissecting the Nycomed case (Case Comment) 3 106

Regulatory data protection
Current status of regulatory data protection for medicinal products in the EU (Article) 2 50
Regulatory data protection of medicinal products from a Swiss perspective (Article) 5 184

Unlicensed medicines
European Court affirms that public safety comes first: financial considerations cannot justify the placing on the market of unlicensed medicines (Case Comment) 4 154
GMC decides not to relax its guidelines to permit broader prescribing of off-label and unlicensed medicines, including on cost-saving grounds (Case Comment) 5 197
PATENTABILITY

Diagnostic treatment
Mayo v Prometheus (United States) 4 167
Mayo v Prometheus: another guidepost to determining patentability in the post-industrial age (Article) 5 175

DNA sequences
Gene sequences are still patentable: the Federal Circuit decides the Myriad Genetics Case (Article) 2 45

PATENTS

Biotechnology
Eli Lilly v HGS round 2 – Warren J (Case Comment) 6 239
Eli Lilly v Human Genome Sciences (United Kingdom) 5 206
Eli Lilly v Human Genome Sciences: has the pro-patentee pendulum swung too far? (Case Comment) 3 100
UK Supreme Court finds industrial application in a biotechnology patent Human Genome Sciences Inc v Eli Lilly and Company (United Kingdom) 2 66

Case management
Patents County Court rules on a blockbuster product: Livesidge v Abbott Laboratories (Case Comment) 6 245

Infringement
High Court finds Regeneron and Bayer's Eylea infringes Genentech patent Regeneron Pharmaceuticals Inc and Bayer Pharma v Genentech Inc (United Kingdom) 5 204
MedImmune judgment gives patent lawyers pause for thought (Case Comment) 1 20
Patents County Court rules on a blockbuster product: Livesidge v Abbott Laboratories (Case Comment) 6 245
UK IPO consultation on exceptions to patent infringement in clinical and field trials (Case Comment) 6 252

Inventions
UK Court considers invalidity on traditional grounds and for lack of technical contribution (Case Comment) 5 192

Legislation
Overview of the proposed legislative framework for the UK Government's Patent Box proposal (Article) 3 90
Patent Box – how is it shaping up? (United Kingdom) 2 69

Mediation
IPO mediation service – call for evidence (United Kingdom) 4 167

Opinions service
Expansion of UKIPO opinions service proposed (United Kingdom) 4 166

Stem cells
Brüstle v Greenpeace: the end of the road for human embryonic stem cell patents (Article) 2 39
Brüstle applied – scientifically flawed but binding? International Stem Cell Corporation (UKIPO) 5 209
Developments in the patentability of inventions relating to human embryonic stem cells (Article) 1 3
Legal status and patentability of human stem cells: a comparative analysis of Australia, the United States and Canada (Article) 4 135
Stemming the tide: no more patents for human embryonic stem cells? (Case Comment) 2 63
UK IPO and EPO issue updated guidelines on patentability of inventions involving human embryonic stem cells Brüstle v Greenpeace e.V. (United Kingdom) 5 207

Supplementary protection certificates
Advocate General’s opinion on Re Medeva’s SPC (Case Comment) 1 24
Negative and zero term SPCs should be granted Merck & Co Inc. v Deutsches Patent- und Markenamt (European News) 2 75
Recent European developments regarding patent extensions (SPCs and paediatric extensions) (Article) 4 123

SPC applications rejected (France) 4 165
SPCs – Advocate General endorses a more expansive approach to eligibility: Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents (Case C-130/11) Opinion of Advocate General Trstenjak (Case Comment) 4 157
SPCs for combination products – where are we now and what is ahead in 2012? (European News) 2 76
Supplementary Protection Certificates: the CJEU issues its decision in two seminal cases (Case Comment) 2 58

Unified Patent Court
Agreement on Unified Patent Court and on unitary patent (European News) 5 202
European unitary patent and unified court: still work in progress (Case Comment) 6 249
Unitary Patent and the European Court: a reality check (Case Comment) 1 27

Unitary patent
Agreement on Unified Patent Court and on unitary patent (European News) 5 202
European unitary patent and unified court: still work in progress (Case Comment) 6 249
Unitary Patent and the European Court: a reality check (Case Comment) 1 27

PHARMACEUTICALS

Directives
Revision of the Clinical Trials Directive (European News) 5 202

Medicinal products
Current status of regulatory data protection for medicinal products in the EU (Article) 2 50

PHARMACOVIGILANCE

Regulation
New legislation comes into effect across the EU (European News) 5 210

PLANT VARIETIES

Exhaustion of rights
Exhaustion of Community plant variety rights clarified Greenstar-Kanzi Europe NV v Jean Hustin and Jo Goossens (European News) 3 110

Royalties
Collection systems for royalties in wheat – an international study (Article) 6 215

STEM CELLS

Patents
Developments in the patentability of inventions relating to human embryonic stem cells (Article) 1 3
Stemming the tide: no more patents for human embryonic stem cells? (Case Comment) 2 63

TAX

Research and development
UK changes to tax relief (News) 2 69

Countries and Institutions

AUSTRALIA

Patents
Legal status and patentability of human stem cells: a comparative analysis of Australia, the United States and Canada (Article) 4 135
CANADA

Patents
Legal status and patentability of human stem cells: a comparative analysis of Australia, the United States and Canada (Article) 4 135

COURT OF JUSTICE OF THE EUROPEAN UNION

Cross-border injunctions
Cross-border injunctions: have they a future? Solvay v Honeywell (European News) 4 161

GMOs
Honey products containing GM pollen require strict marketing control in the EU Karl Heinz Bablok and others v Freistaat Bayern (European News) 2 74

Medicinal products
European Court affirms that public safety comes first: financial considerations cannot justify the placing on the market of unlicensed medicines (Case Comment) 4 154

Patents
Brüstle v Greenpeace: the end of the road for human embryonic stem cell patents (Article) 2 39
Developments in the patentability of inventions relating to human embryonic stem cells (Article) 1 3
Stemming the tide: no more patents for human embryonic stem cells? (Case Comment) 2 63

Plant varieties
Exhaustion of Community plant variety rights clarified Greenstar-Kanzi Europe NV v Jean Hustin and Jo Goossens (European News) 3 110

Supplementary Protection Certificates
Advocate General’s opinion on Re Medeva’s SPC (Case Comment) 1 24
Negative and zero term SPCs should be granted Merck & Co Inc. v Deutsches Patent- und Markenamt (European News) 2 75
SPCs – Advocate General endorses a more expansive approach to eligibility: Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents (Case C–130/11) Opinion of Advocate General Trstenjak (Case Comment) 4 157
SPCs for combination products – where are we now and what is ahead in 2012? (European News) 2 76
Supplementary Protection Certificates: the CJEU issues its decision in two seminal cases (Case Comment) 2 58

EUROPEAN COMMISSION

Medicinal products
New framework for provision of information to the general public about prescription-only medicines (European News) 2 71

Pharmaceuticals
Revision of the Clinical Trials Directive (European News) 5 202

EUROPEAN MEDICINES AGENCY (EMEA)

Biosimilars
Biosimilar guidelines – new consultation opportunity (European News) 2 78

Gene therapy
First gene therapy product recommended for approval in the EU (European News) 5 201

EUROPEAN PATENT OFFICE

Patentability
Developments in the patentability of inventions relating to human embryonic stem cells (Article) 1 3
UK IPO and EPO issue updated guidelines on patentability of inventions involving human embryonic stem cells Brüstle v Greenpeace e.V. (United Kingdom) 5 207

EUROPEAN UNION

Medicinal products
Current status of regulatory data protection for medicinal products in the EU (Article) 2 50

Patents
Agreement on court and on unitary patent (European News) 5 202
European unitary patent and unified court: still work in progress (Case Comment) 6 249
Unitary Patent and the European Court: a reality check (Case Comment) 1 27

Supplementary protection certificates
Recent European developments regarding patent extensions (SPCs and paediatric extensions) (Article) 4 123

FRANCE

Patents
SPC applications rejected (News) 4 165

GENERAL COURT OF THE EUROPEAN UNION

Medicinal products
Dissecting the Nycomed case (Case Comment) 3 106

INTERNATIONAL

Plant variety royalties
Collection systems for royalties in wheat – an international study (Article) 6 215

SWITZERLAND

Regulatory data protection
Regulatory data protection of medicinal products from a Swiss perspective (Article) 5 184

TURKEY

GMOs
Authorisation regime for GM food and feed in Turkey under the new GMO legislation: the simplified procedure proves simply too irresistible for applicants (Article) 1 8

UNITED KINGDOM

Contracts
Common sense approach to entire agreement clauses Axa Sun Life v Campbell Martin; BSkyB v HP Enterprise Services (News) 3 112

Healthcare
Health and Social Care Act promises to improve competition in healthcare (News) 3 113

Life sciences agreements
Deferred consideration and diligence obligations in life sciences agreements: the lessons from Porton Capital Technology Funds (and others) v 3M (Article) 3 83
Medicinal products
GMC decides not to relax its guidelines to permit broader prescribing of off-label and unlicensed medicines, including on cost-saving grounds (Case Comment) 5 197

Patents
Brüstle applied – scientifically flawed but binding? International Stem Cell Corporation (UKIPO) 5 209
Eli Lilly v HGS round 2 – Warren J (Case Comment) 6 239
Eli Lilly v Human Genome Sciences: has the pro-patentee pendulum swung too far? (Case Comment) 3 100
Expansion of UKIPO opinions service proposed (News) 4 166
High Court finds Regeneron and Bayer's Eylea infringes Genentech patent Regeneron Pharmaceuticals Inc and Bayer Pharma v Genentech Inc (News) 5 204
IPO mediation service – call for evidence (News) 4 167
MedImmune judgment gives patent lawyers pause for thought (Case Comment) 2 20
Overview of the proposed legislative framework for the UK Government's Patent Box proposal (Article) 3 90
Patent Box – how is it shaping up? (News) 2 69
Patents County Court rules on a blockbuster product: Livisides v Abbott Laboratories (Case Comment) 6 265
Supreme Court finds industrial application in a biotechnology patent Human Genome Sciences Inc v Eli Lilly and Company (News) 2 66
UK Court considers invalidity on traditional grounds and for lack of technical contribution (Case Comment) 5 192
UK IPO and EPO issue updated guidelines on patentability of inventions involving human embryonic stem cells Brüstle v Greenpeace e.V. (News) 5 207
UK IPO consultation on exceptions to patent infringement in clinical and field trials (Case Comment) 6 252

Pharmaceuticals
Pharmacovigilance – new legislation comes into effect across the EU (News) 5 210

Tax
Research and development tax relief changes (News) 2 69

UNITED STATES
Patentability
Gene sequences are still patentable: the Federal Circuit decides the Myriad Genetics Case (Article) 2 45
Mayo v Prometheus (News) 4 167
Mayo v Prometheus: another guidepost to determining patentability in the post-industrial age (Article) 5 175

Patents
Legal status and patentability of human stem cells: a comparative analysis of Australia, the United States and Canada (Article) 4 135

WORLD INTERNATIONAL PROPERTY ORGANIZATION

Contributors
Abbott, Paul (Case Comment) 6 239
Antcliff, Jennifer (News) 2 66
Artemel, Mehmet (Article) 1 8
Bassil, Nick (Article) 3 3
Bernardi, Céline (News) 4 165
Bernhardt, Jeffery (Article) 2 45
Blakeney, Michael (News) 3 115; (Book Reviews) 1 32, 1 34, 2 79, 3 117, 3 119, 4 170, 4 171
Bryden, Duncan (News) 3 112
Clark, Vicky (Article) 3 83
Cline, Helen (News) 4 164, 4 166, 4 167, 5 202, 5 210
Cook, Trevor (Article) 2 50
Counihan, Robert (Article) 5 175; (News) 4 167
Craig, Richard (News) 3 113
Curtis, Frank (ed.) (Article) 6 213
Davies, Nikol (News) 2 65, 3 114
De Coster, Christoph (Case Comment) 1 27; (News) 2 75
Douma, Tijbbe (Article) 4 123
Farmer, Stacey J (Article) 2 39
Fox, James (Article) 2 45
Gilbert, Penny (Case Comment) 2 63
Grund, Martin (Article) 2 39
Hayes, Christopher (Case Comment) 4 157
Holzer, Simon (Article) 5 184
Hopewell, Bethan (News) 2 66
Howell, Andrew (News) 3 112
Innes, Sarah (Case Comment) 1 24
Jackson, Stuart (Case Comments) 1 20, 3 100, 6 245
Kamstra, Gerry (Book Review) 5 211
Kariyawasam, Kanchana (Article) 4 135
Kempner, Richard (Case Comment) 3 100
Kilkic, James (Case Comments) 4 154, 5 197
Kokke, Margot (Article) 4 123
Kritikos, Mihalis (Case Comments) 4 154, 5 197
Kuipers, Gerritjan (Article) 4 123
Kumar, Dev (Case Comment) 3 106
Lees, Geoff (Case Comment) 2 63
Lunze, Anja (News) 2 75, 4 161
Manley, Maria Isabel (Case Comment) 3 100
Miles, John (Case Comment) 2 58
Morgan, Gareth (Case Comment) 1 24
Nargolwalla, Cyra (News) 4 165
Nickless, David (News) 5 207
Nilsson, Malin (ed.) (Article) 6 213
O'Sullivan, Nina (News) 5 204
Pears, Michael (Case Comment) 2 58
Penny, Louisa (News) 3 113
Plomley, Jane (Article) 5 175
Puran, Sangeeta (Article) 3 90
Pygall, Alexandra (Case Comment) 6 252
Roberts, Michael A (News) 2 74, 3 100
Roberts, Tim (Book Review) 6 255
Royle, Matthew (News) 2 76, 2 78, 5 201, 5 206, 5 209
Sant, David Paul (Case Comments) 1 27, 6 249
Shkopiak, Talitha (News) 5 202
Singer, Juliet (Case Comment) 5 192
Snodin, Mike (Case Comment) 2 58
Stothers, Christopher (Case Comment) 6 239
Touati, Catherine (News) 4 165
Vere-Hodge, Till (News) 2 71
Vidal, Robert (News) 3 113
Weeks, Charlotte (Case Comment) 5 192
Whitehead, Brian (Case Comments) 1 20, 3 100, 6 245
Williamson, Michelle (News) 2 69

Contributions
ARTICLES
Authorisation regime for GM food and feed in Turkey under the new GMO legislation: the simplified procedure proves simply too irresistible for applicants Professor Mehmet Artemel 1 8
Brüstle v Greenpeace: the end of the road for human embryonic stem cell patents Dr Martin Grund and Dr Stacey J Farmer 2 39
Collection systems for royalties in wheat – an international study Frank Curtis and Malin Nilsson (eds) 6 215
Current status of regulatory data protection for medicinal products in the EU Trevor Cook 2 50
Deferred consideration and diligence obligations in life sciences agreements: the lessons from Porton Capital Technology Funds (and others) v 3M Vicky Clark 3 83
Developments in the patentability of inventions relating to human embryonic stem cells Nick Bassil 1 3
Gene sequences are still patentable: the Federal Circuit decides the Myriad Genetics Case Jeffrey Bernhardt and James Fox 2 45
Legal status and patentability of human stem cells: a comparative analysis of Australia, the United States and Canada Dr Kanchana Kariyawasam 4 135
Mayo v Prometheus: another guidepost to determining patentability in the post-industrial age Jane Plonley and Robert Counihan 5 175
Overview of the proposed legislative framework for the UK Government's Patent Box proposal Songeta Puran 3 90
Recent European developments regarding patent extensions (SPCs and paediatric extensions) Gertjan Kuipers, Tjibbe Douma and Margot Kokke 4 123
Regulatory data protection of medicinal products from a Swiss perspective Dr Simon Holzer 5 184

CASE COMMENTS
Advocate General's opinion on Re Medeva's SPC Dr Gareth Morgan and Sarah Innes 1 24
Dissecting the Nycombe case Maria Isabel Manley and Dr Dev Kumarr 3 106
Eli Lilly v HGS round 2 – Warren J Paul Abbott and Christopher Stathers 6 239
Eli Lilly v Human Genome Sciences: has the pro-patentee pendulum swung too far? Brian Whitehead, Stuart Jackson and Richard Kemper 3 500
European Court affirms that public safety comes first: financial considerations cannot justify the placing on the market of unlicensed medicines James Killick and Dr Mihalis Kritikos 4 154
European unitary patent and unified court: still work in progress David Paul Sant 6 249
GMC decides not to relax its guidelines to permit broader prescribing of off-label and unlicensed medicines, including on cost-saving grounds James Killick and Dr Mihalis Kritikos 5 197
Liversidge v Abbott Laboratories 6 245
MedImmune judgment gives patent lawyers pause for thought Dr Brian Whitehead and Stuart Jackson 1 20
Patents County Court rules on a blockbuster product: Liversidge v Abbott Laboratories Brian Whitehead and Stuart Jackson 6 245
SPCs – Advocate General Endorses a more expansive approach to eligibility: Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents (Case C–130/11) Opinion of Advocate General Trstenjak Dr Christopher Hayes 4 157
Stemming the tide: no more patents for human embryonic stem cells? Penny Gilbert and Geoff Lees 2 63
Supplementary Protection Certificates: the CJEU issues its decision in two seminal cases Dr Mike Snodin, Dr John Miles and Dr Michael Pears 2 58
UK Court considers invalidity on traditional grounds and for lack of technical contribution Juliet Singer and Charlotte Weekes 5 192
UK IPO consultation on exceptions to patent infringement in clinical and field trials Alexandra Pygall 6 252
Universal Patent and the European Court: a reality check David Paul Sant 1 27

BOOK REVIEWS
Genetic Resources and Traditional Knowledge. Case studies and conflicting interests (Tania Babula and Richard Gold, eds) Michael Blakeney 4 171
Governing Biobanks – understanding the interplay between law and practice (Jane Kaye, Susan McGibbons, Catherine Heeney, Michael Parker and Andrew Smart) Gerry Kamstra 5 211
Intellectual Property and Biotechnology (Arti K Rai, ed.) Michael Blakeney 1 32
Intellectual Property and Climate Change. Inventing clean technologies (Matthew Rimmer) Michael Blakeney 3 117
Intellectual Property and Sustainable development: development agendas in a changing world (Ricardo Meléndez-Ortiz and Pedro Roffe, eds) Michael Blakeney 4 170
International Patent Law: Cooperation, harmonization and an institutional analysis of WIPO and the WTO (Alexander Stack) Michael Blakeney 2 79
New Frontiers in the Philosophy of Intellectual Property (Annabelle Lever, ed.) Tim Roberts 6 255
Structure of Intellectual Property Law. Can one size fit all? (Annette Kur and Vytautas Mizuras, eds) Michael Blakeney 1 34

Case List
Association for Molecular Pathology et al. v U.S. Patent & Trademark Office et al. (US Court of Appeals for the Federal Circuit) 2011 2 45
Asa Sun Life v Campbell Martin [2011] EWCA Civ 133 3 112
Brustle v Greenpeace (CJEU) Case C-34/10 2 39, 2 63, 5 207
BSkyB v HP Enterprise Services [2010] EWHC 86 (TCC) 1 212
Commission v Poland (CJEU) Case C-185/10 4 154
Eli Lilly and Company v Human Genome Sciences, Inc. [2012] EWCA Civ 1185 5 206, 6 239
Generics (UK) Limited trading as Mylan v (i) Yeda Research and Development Co Ltd (2) Teva Pharmaceutical Industries Limited [2012] EWHC 1848 (Pat) 5 192
Greenstar-Kanz Europe NV v Jean Humin and Jo Goossens (CJEU) Case C-140/10 3 110
Human Genome Sciences Inc v Eli Lilly and Company [2011] UKSC 51 2 66, 3 100
International Stem Cell Corporation (UKIPO) BL 0/316/12 5 209
Karl Heinz Bakbolk and others v Freistaat Bayern (CJEU) Case C-442/10 2 74
Mayo Collaborative Services v Prometheus Labs, Inc. (United States) 4 167, 5 175
Medeva BV (CJEU) Case C-322/10 2 58, 2 76
Medeva's SPC Applications, re [2020] EWHC 68 (Pat) 1 24
MedImmune Limited v Novartis Pharmaceuticals UK Limited and Medical Research Council [2011] EWHC 1669 (Pat) 1 20
Merck & Co Inc. v Deutsche Patent- und Markenamt (CJEU) Case C-125/10 2 59, 2 76
Nymcode Danmark ApS v European Medicines Agency (General Court) Case T-52/09 3 106
Porton Capital Technology Funds (and others) v 3M (QBD (Commercial Court)) 2 83
Regeneron Pharmaceuticals Inc and Bayer Pharma v Genentech Inc, 22 March 2012, 5 204
Solvay v Honeywell (CJEU) Case C-616/10 4 161